Inhibikase Therapeutics 株価情報 (NASDAQ: IKT)

最新ニュース Inhibikase Therapeutics (NASDAQ:IKT) 株価情報

Inhibikase Therapeutics

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics Inc

iTokk Inc

INTERTEK GROUP PLC ORD by Intertek Group Plc

Intertek Group PLC

INTERTEK GROUP UNSP/ADR by Intertek Group Plc

Barrington Research analyst Alexander Paris maintains H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) with a Outperform and maintains $70 price target.

News

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on H&R Block, Maintains $70 Price Target

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and maintains $2.25 price target.

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

Macquarie analyst Tim Nollen maintains Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a Neutral and raises the price target from $8 to $9.

Macquarie Maintains Neutral on Warner Bros. Discovery, Raises Price Target to $9

BWS Financial analyst Hamed Khorsand maintains Arlo Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) with a Buy and maintains $24 price target.

ARLO

BWS Financial Maintains Buy on Arlo Technologies, Maintains $24 Price Target

Jones Trading analyst Matthew Erdner maintains Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) with a Buy and raises the price target from $6.5 to $7.

REAX

Jones Trading Maintains Buy on Real Brokerage, Raises Price Target to $7

Macquarie analyst Chad Beynon maintains Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) with a Outperform and lowers the price target from $65 to $64.

Macquarie Maintains Outperform on Red Rock Resorts, Lowers Price Target to $64

Macquarie analyst Chad Beynon maintains PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) with a Outperform and raises the price target from $26 to $27.

PENN

Macquarie Maintains Outperform on PENN Entertainment, Raises Price Target to $27

Donald Trump&#8216;s winning the 2024 presidential election is expected to have a negative impact on <a href="https://www.benzinga.com/electric-vehicles">the electric vehicle sector</a>.
Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) could benefit from CEO Elon Musk's close relationship <a href="https://www.benzinga.com/markets/equities/24/11/41832876/elon-musk-shines-in-trump-sweepstakes-a-big-win-for-tesla-dan-ives-thinks-so">with the president-elect</a>. However, the company&#8217;s plan to build a Gigafactory in Mexico could be at stake.
What Happened: Tesla reportedly <a href="https://www.benzinga.com/news/24/02/37305137/tesla-to-kick-off-construction-of-giga-mexico-next-week-nuevo-le-n-governor-confirms">plans to build a gigafactory </a>in Mexico. The facility could produce sub-$30,000 vehicles, Model Y units, batteries and the Cybertruck.
Tesla hasn't confirmed its plans in Mexico. Still, the country's economic minister is asking questions after Trump won on Election Day.
"I'm going to set up a meeting with (Musk) soon so that he tells me exactly what he's thinking and see what we can do so this project moves forward," Mexico Economy Minister Marcelo Ebrard told local radio Thursday, as reported by Reuters.
Original plans for Mexico and other new factory locations may <a href="https://www.benzinga.com/news/23/06/33053957/tesla-gigafactory-mexico-opening-reportedly-delayed-to-early-2025-amid-logistical-hurdles">have been delayed</a> due to the election with Tesla saying in April that it would use its existing factories to build new more affordable vehicles.
Trump's past term in the White House put pressure on foreign-made items shipped to the United States. Prior to the 2024 election win, Trump<a href="https://www.benzinga.com/news/24/10/41397317/trump-defends-his-plans-to-impose-200-tariffs-on-cars-imported-from-china-mexico-hope-union-workers"> has been promising</a> to put a 200% tariff on vehicles imported from China and Mexico.
Tesla did not respond to a request for comment on its plans in Mexico to Benzinga.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Tesla has several gigafactories around the world that produce and export vehicles to key regions like Europe and Asia.
A gigafactory in Mexico was likely less about exports to other countries and more about bringing vehicles into the U.S.
Investors and analysts will continue monitoring Trump's win and whether it impacts Tesla and the EV sector.
Price Action: Tesla stock closed Friday up 8.1% to $321.22. The company hit a new 52-week high of $328.71 during the trading session. Tesla stock is up 31.5% over the last five days and up 29.3% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41501607/tesla-q3-earnings-highlights-eps-beat-revenue-miss-shares-climb-on-2025-timeline-for-lower-cost-evs">Tesla Q3 Earnings Highlights: EPS Beat, Revenue Miss, Shares Climb On 2025 Timeline For Lower-Cost EVs</a></li>
</ul>
Image: Shutterstock

Politics

Trading Ideas

TSLA

Elon Musk To Ditch Tesla Gigafactory In Mexico After Trump's Win? Economy Minister Wants 'A Meeting'

Macquarie analyst Chad Beynon maintains Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) with a Outperform and lowers the price target from $39 to $38.

GDEN

Macquarie Maintains Outperform on Golden Entertainment, Lowers Price Target to $38

Macquarie analyst Tim Nollen maintains Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) with a Underperform and raises the price target from $15 to $16.

Macquarie Maintains Underperform on Unity Software, Raises Price Target to $16

Macquarie analyst Tim Nollen maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Outperform and raises the price target from $130 to $133.

Macquarie Maintains Outperform on Trade Desk, Raises Price Target to $133

Macquarie analyst Tim Nollen maintains Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Outperform and maintains $18 price target.

MGNI

Macquarie Maintains Outperform on Magnite, Maintains $18 Price Target

WIIM

REVB

Revelation Biosciences shares are trading higher after the company reported better-than-expected Q3 EPS results.

NPABU

Trading Halt: Halt status updated at 4:40:00 PM ET: Quotation Resumption: News and Resumption Times

NPAB

Trading Halt: Halt status updated at 4:35:00 PM ET: Quotation Resumption: News and Resumption Times

Earnings

Associated Cap Gr Q3 EPS $1.09

The second of three monthly contests in Benzinga's paper trading competition powered by TradeZero kicked off on Oct. 15, giving contestants a chance to take home a portion in the more than $30,000 in cash and prizes offered during&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">the three-month run.</a>
With one week left in the competition, the top of the leaderboard is close with new leaders emerging, including the first contest winner.
The Contests:&nbsp;Powered by&nbsp;TradeZero, the&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">World Championship of Trading</a>&nbsp;is the ultimate trading competition for investors to prove their keen eye during a three-month time period.
The first of three separate contests kicked off on Monday, Sept. 16. Over $5,000 in cash will be awarded to verified contest winners from the first contest.
With the first contest over, everyone who signs up for the second will now compete for the top prize of $10,000 in cash, a lifetime of Benzinga Pro Essential and a tour of the New York Stock Exchange with lunch for two at the exchange.
Contestants have until Nov. 7 to sign up for the second contest, with everyone starting over with a paper balance of $100,000. Based on the last contest&#8217;s results, investors may want to sign up and start trading today.
Each investor will have around one month across three separate contests to generate the highest profits from a starting balance of $100,000 in a simulated trading account.
Contestants in the World Championship of Trading will have access to Benzinga's Live Squawk product.
Investors will also gain exposure to TradeZero's newly patented short-selling tools.
Through Nov. 3 this is the current leaderboard for the second contest:
1st: Shruthi M.: $489,637.60
2nd: Andrea S.: $416,220.00
3rd: XiaoTian Z.: $302,710.00
Each of the top 10 contestants on the leaderboard has a balance of at least $197,290.00.
<a href="https://www.benzinga.com/exclusives/24/10/41666928/benzinga-world-championship-of-trading-powered-by-tradezero-top-trader-is-up-over-600-think-you-can">Last week's leader </a>XiaoTian Z. fell to third place. Shruthi M., who now leads the way, was in fourth place last week. The first contest winner Andrea S. has soared to second place after not being on the leaderboard last week.
This week's top 10 features only five of the top 10 from last week, which shows how the leaderboard changes. This means even if you missed the second contest deadline, you should have the upcoming contests on your radar, as anyone can win with some patience and good trades.
First Contest Winner:&nbsp;Andrea S., the winner of the first contest, went from $100,000 to more than $1 million in the paper trading account in&nbsp;<a href="https://www.benzinga.com/exclusives/24/10/41240862/benzinga-world-championship-of-trading-powered-by-tradezero-1-contestant-up-988-in-3-weeks-join-now" target="_blank" rel="noreferrer noopener">less than a month.</a>
Benzinga previously <a href="https://www.youtube.com/live/DjRmtokM2YQ?si=V0zxoFo4dHh0jPGT&amp;start=3615" target="_blank" rel="noreferrer noopener">interviewed </a>Andrea S., who was in the top 10 for most of the contest and was in first place several weeks.
Contest Rules:&nbsp;The contest is open to residents of the United States and Canada who are 21 years of age or older.
Traders will be able to buy simulated equities and options from U.S. markets during the contest periods starting with a balance of $100,000. No fractional shares will be allowed. Traders have to hold a minimum of one stock or option throughout the contest. A minimum of five days of one trade or more must be completed throughout each contest.
Interested investors have been able to&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">sign up to join</a>&nbsp;the contest since Friday, July 26. Signing up for the first contest will automatically register an entry in the second and third contests. Traders can sign up for the contests after the start dates as long as it is before a cutoff deadline.
The dates for the&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">contests</a>&nbsp;are listed below:
<ul>
<li>Contest 1: Sept. 15 through Oct. 14</li>
<li>Contest 2: Oct. 15 through Nov. 14</li>
<li>Contest 3: Nov. 15 through Dec. 14</li>
</ul>
The last days to register for the remaining contests are at 9 a.m. ET on Nov. 7 and Dec. 8.
Read Also:&nbsp;<a href="https://www.benzinga.com/fintech/23/11/35687369/tradezero-ceo-daniel-pipitone-giving-the-retail-traders-an-institutional-level-toolbox" target="_blank" rel="noreferrer noopener">TradeZero CEO Daniel Pipitone: Giving Retail Traders An Institutional-Level Toolbox</a>
Contest Prizes: Participants have the chance to win as much as $30,000 in cash and prizes during the contests. Travel and expenses will not be paid for the NYSE tour prizes.
Here are the prizes for the World Championship of Trading.
Contest 1:
<ul>
<li>First Place: $5,000 cash, lifetime of&nbsp;<a href="https://pro.benzinga.com/feature/newsfeed/?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348" target="_blank" rel="noreferrer noopener">Benzinga Pro Essential,</a>&nbsp;tour of the NYSE and lunch for two at the NYSE.</li>
<li>Second Place: $1,000 cash, one year of Benzinga Pro Essential.</li>
<li>Third Place: $500 cash, one year of Benzinga Pro Essential.</li>
</ul>
Contest 2:
<ul>
<li>First Place: $10,000 cash, lifetime of Benzinga Pro Essential, tour of the NYSE and lunch for two at the NYSE.</li>
<li>Second Place: $2,000 cash, one year of Benzinga Pro Essential.</li>
<li>Third Place: $1,000 cash, one year of Benzinga Pro Essential.</li>
</ul>
Contest 3:
<ul>
<li>First Place: $15,000 cash, lifetime of Benzinga Pro Essential, tour of the NYSE and lunch for two at the NYSE.</li>
</ul>
Find out more at the&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">World Championship of Trading site</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a></li>
</ul>
The World Championship of Trading (the "Contest") involves the assembling and managing of a fantasy stock portfolio and not actual trading results. Contest information and results (collectively, the &#8220;Content&#8221;) have been made available for information and entertainment purposes only and should not be considered trading or investment advice or a recommendation as to any security. All trading involves risks. Neither Benzinga nor TradeZero make any representations and warranties with respect to the accuracy of the Content, nor do they accept any liability which may arise directly or indirectly from use of the Content. See the&nbsp;<a href="https://tradezeroedge.com/world-championship-of-trading/contest-instructions" target="_blank" rel="noreferrer noopener">Contest's official rules</a>&nbsp;for all terms and conditions. TradeZero provides self-directed brokerage accounts to customers through its operating affiliates: TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas; and TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of the Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF). If you have any specific questions about TradeZero&#8217;s brokerage services, please reach out to the TradeZero broker dealer in your jurisdiction.

Exclusives

Benzinga World Championship Of Trading Powered By TradeZero Top Trader Is Up Over 400% In Second Contest, First Contest Winner Ranks Second

Management

RDUS

Radius Recycling Appoints Marc Hathhorn As COO

Macquarie analyst Aaron Lee maintains Playtika Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) with a Neutral and maintains $7 price target.

PLTK

Macquarie Maintains Neutral on Playtika Holding, Maintains $7 Price Target

OPOF

Old Point Financial Corporation Appoints Cathy W. Liles As CFO

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inhibikase Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ikt-stock-quote/">IKT</a>) just reported results for the second quarter of 2024.<ul><li>Inhibikase Therapeutics reported earnings per share of -66 cents. This was above the analyst estimate for EPS of -67 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ikt-stock-earnings-inhibikase-therapeutics-for-q2-of-2024/">IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024

Inhibikase Therapeutics GAAP EPS of -$0.66 beats by $0.01

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Inhibikase Therapeutics ( ($IKT) ) has provided an announcement. Inhibikase Therapeutics, Inc. released a new presentation on their website detaili...

Inhibikase Therapeutics Unveils PAH and Parkinson's Drug Pipeline

Inhibikase Therapeutics stock rises after pricing $110M private offering

Inhibikase Therapeutics ( ($IKT) ) has shared an update. Inhibikase Therapeutics, Inc. has entered into an agreement for a private placement transa...

Inhibikase Therapeutics Secures $110M for Drug Development

Inhibikase Therapeutics (IKT) announced the closing of a private placement of approximately $110 Million from the issuance and sale of shares of th...

Inhibikase Therapeutics closes up to $275M financing, advances IkT-001Pro

Inhibikase Therapeutics ( ($IKT) ) has shared an update. Inhibikase Therapeutics, Inc. has secured approximately $110 million through a private pla...

Inhibikase Therapeutics Secures Funding and Strengthens Leadership

Jefferies initiated coverage of Inhibikase Therapeutics (IKT) with a Buy rating and $8 price target The stock looks inexpensive as its novel imatin...

Inhibikase Therapeutics initiated with a Buy at Jefferies

Inhibikase Therapeutics (IKT) has received a new Buy rating, initiated by Jefferies analyst, Dennis Ding. Dennis Ding has given his Buy rating due ...

Inhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy Rating

Health Care

Press Releases

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

General

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Atossa Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Candel Therapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Cardiff Oncology

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Gossamer Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Nanobiotix

Nuvectis Pharma

PepGen

Sagimet Biosciences Inc. - Series A Common Stock

Comments

Inhibikase Therapeutics

ニュース

最新ニュース Inhibikase Therapeutics (NASDAQ:IKT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル